floxuridine + dexamethasone + oxaliplatin + leucovorin + 5-fluorouracil

This combination therapy regimen consists of hepatic arterial infusion (HAI) of floxuridine and dexamethasone administered concurrently with systemic mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil). This specific protocol is being evaluated in clinical trials led by Yuhong Li at Sun Yat-sen University for the treatment of patients with initially unresectable colorectal liver metastases. The HAI component delivers high concentrations of floxuridine directly to the liver via the hepatic artery, exploiting the fact that liver metastases derive their blood supply primarily from the hepatic artery, while the systemic mFOLFOX6 component addresses potential extrahepatic disease. Floxuridine and 5-fluorouracil are pyrimidine analogs that inhibit DNA synthesis by targeting thymidylate synthase, oxaliplatin is a platinum-based DNA alkylator, and leucovorin is used to potentiate the effects of the fluoropyrimidines. Dexamethasone is included in the HAI pump to mitigate biliary toxicity and hepatotoxicity associated with continuous floxuridine infusion.

Other names

HAI-Yuhong Li-colorectal cancer metastatic to livermFOLFOX6 plus HAI floxuridine and dexamethasonemFOLFOX-6 plus HAI floxuridine and dexamethasonemFOLFOX 6 plus HAI floxuridine and dexamethasoneHepatic Arterial Infusion with Floxuridine and Dexamethasone plus systemic mFOLFOX6